Global Constipation Treatment Market Size, Top Share Report to 2031

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Constipation Treatment Market Size Analysis

Global Constipation Treatment Market Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Mu-Opioid Receptor Antagonists
  1. By Value
3. Laxative
  1. By Value
4. Chloride Channel-2 Activator
  1. By Value
5. Guanylate Cyclase-C (GC-C) Agonist
  1. By Value
6. Others
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Opioid-Induced Constipation
  1. By Value
3. Chronic Idiopathic Constipation
  1. By Value
4. Irritable Bowel Syndrome with Constipation
  1. By Value
By Prescription Type
1. Introduction
  1. Prescription Type By Value
2. Prescribed Drugs
  1. By Value
3. Over-the-Counter Drugs
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Online Pharmacy
  1. By Value
3. Drug Store and Retail Pharmacy
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Mu-Opioid Receptor Antagonists
  1. By Value
3. Laxative
  1. By Value
4. Chloride Channel-2 Activator
  1. By Value
5. Guanylate Cyclase-C (GC-C) Agonist
  1. By Value
6. Others
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Opioid-Induced Constipation
  1. By Value
3. Chronic Idiopathic Constipation
  1. By Value
4. Irritable Bowel Syndrome with Constipation
  1. By Value
By Prescription Type
1. Introduction
  1. Prescription Type By Value
2. Prescribed Drugs
  1. By Value
3. Over-the-Counter Drugs
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Online Pharmacy
  1. By Value
3. Drug Store and Retail Pharmacy
  1. By Value
4. Others
  1. By Value
U.S.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Mu-Opioid Receptor Antagonists
    1. By Value
  3. Laxative
    1. By Value
  4. Chloride Channel-2 Activator
    1. By Value
  5. Guanylate Cyclase-C (GC-C) Agonist
    1. By Value
  6. Others
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Opioid-Induced Constipation
    1. By Value
  3. Chronic Idiopathic Constipation
    1. By Value
  4. Irritable Bowel Syndrome with Constipation
    1. By Value
3. By Prescription Type
  1. Introduction
    1. Prescription Type By Value
  2. Prescribed Drugs
    1. By Value
  3. Over-the-Counter Drugs
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Online Pharmacy
    1. By Value
  3. Drug Store and Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Mu-Opioid Receptor Antagonists
  1. By Value
3. Laxative
  1. By Value
4. Chloride Channel-2 Activator
  1. By Value
5. Guanylate Cyclase-C (GC-C) Agonist
  1. By Value
6. Others
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Opioid-Induced Constipation
  1. By Value
3. Chronic Idiopathic Constipation
  1. By Value
4. Irritable Bowel Syndrome with Constipation
  1. By Value
By Prescription Type
1. Introduction
  1. Prescription Type By Value
2. Prescribed Drugs
  1. By Value
3. Over-the-Counter Drugs
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Online Pharmacy
  1. By Value
3. Drug Store and Retail Pharmacy
  1. By Value
4. Others
  1. By Value
U.K.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Mu-Opioid Receptor Antagonists
    1. By Value
  3. Laxative
    1. By Value
  4. Chloride Channel-2 Activator
    1. By Value
  5. Guanylate Cyclase-C (GC-C) Agonist
    1. By Value
  6. Others
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Opioid-Induced Constipation
    1. By Value
  3. Chronic Idiopathic Constipation
    1. By Value
  4. Irritable Bowel Syndrome with Constipation
    1. By Value
3. By Prescription Type
  1. Introduction
    1. Prescription Type By Value
  2. Prescribed Drugs
    1. By Value
  3. Over-the-Counter Drugs
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Online Pharmacy
    1. By Value
  3. Drug Store and Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Mu-Opioid Receptor Antagonists
  1. By Value
3. Laxative
  1. By Value
4. Chloride Channel-2 Activator
  1. By Value
5. Guanylate Cyclase-C (GC-C) Agonist
  1. By Value
6. Others
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Opioid-Induced Constipation
  1. By Value
3. Chronic Idiopathic Constipation
  1. By Value
4. Irritable Bowel Syndrome with Constipation
  1. By Value
By Prescription Type
1. Introduction
  1. Prescription Type By Value
2. Prescribed Drugs
  1. By Value
3. Over-the-Counter Drugs
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Online Pharmacy
  1. By Value
3. Drug Store and Retail Pharmacy
  1. By Value
4. Others
  1. By Value
China
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Mu-Opioid Receptor Antagonists
    1. By Value
  3. Laxative
    1. By Value
  4. Chloride Channel-2 Activator
    1. By Value
  5. Guanylate Cyclase-C (GC-C) Agonist
    1. By Value
  6. Others
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Opioid-Induced Constipation
    1. By Value
  3. Chronic Idiopathic Constipation
    1. By Value
  4. Irritable Bowel Syndrome with Constipation
    1. By Value
3. By Prescription Type
  1. Introduction
    1. Prescription Type By Value
  2. Prescribed Drugs
    1. By Value
  3. Over-the-Counter Drugs
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Online Pharmacy
    1. By Value
  3. Drug Store and Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Mu-Opioid Receptor Antagonists
  1. By Value
3. Laxative
  1. By Value
4. Chloride Channel-2 Activator
  1. By Value
5. Guanylate Cyclase-C (GC-C) Agonist
  1. By Value
6. Others
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Opioid-Induced Constipation
  1. By Value
3. Chronic Idiopathic Constipation
  1. By Value
4. Irritable Bowel Syndrome with Constipation
  1. By Value
By Prescription Type
1. Introduction
  1. Prescription Type By Value
2. Prescribed Drugs
  1. By Value
3. Over-the-Counter Drugs
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Online Pharmacy
  1. By Value
3. Drug Store and Retail Pharmacy
  1. By Value
4. Others
  1. By Value
UAE
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Mu-Opioid Receptor Antagonists
    1. By Value
  3. Laxative
    1. By Value
  4. Chloride Channel-2 Activator
    1. By Value
  5. Guanylate Cyclase-C (GC-C) Agonist
    1. By Value
  6. Others
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Opioid-Induced Constipation
    1. By Value
  3. Chronic Idiopathic Constipation
    1. By Value
  4. Irritable Bowel Syndrome with Constipation
    1. By Value
3. By Prescription Type
  1. Introduction
    1. Prescription Type By Value
  2. Prescribed Drugs
    1. By Value
  3. Over-the-Counter Drugs
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Online Pharmacy
    1. By Value
  3. Drug Store and Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Mu-Opioid Receptor Antagonists
  1. By Value
3. Laxative
  1. By Value
4. Chloride Channel-2 Activator
  1. By Value
5. Guanylate Cyclase-C (GC-C) Agonist
  1. By Value
6. Others
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Opioid-Induced Constipation
  1. By Value
3. Chronic Idiopathic Constipation
  1. By Value
4. Irritable Bowel Syndrome with Constipation
  1. By Value
By Prescription Type
1. Introduction
  1. Prescription Type By Value
2. Prescribed Drugs
  1. By Value
3. Over-the-Counter Drugs
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Online Pharmacy
  1. By Value
3. Drug Store and Retail Pharmacy
  1. By Value
4. Others
  1. By Value
Brazil
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Mu-Opioid Receptor Antagonists
    1. By Value
  3. Laxative
    1. By Value
  4. Chloride Channel-2 Activator
    1. By Value
  5. Guanylate Cyclase-C (GC-C) Agonist
    1. By Value
  6. Others
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Opioid-Induced Constipation
    1. By Value
  3. Chronic Idiopathic Constipation
    1. By Value
  4. Irritable Bowel Syndrome with Constipation
    1. By Value
3. By Prescription Type
  1. Introduction
    1. Prescription Type By Value
  2. Prescribed Drugs
    1. By Value
  3. Over-the-Counter Drugs
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Online Pharmacy
    1. By Value
  3. Drug Store and Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Constipation Treatment Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Sanofi
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Takeda
Abbvie
Abbott
Bausch Health
Bayer
Astrazeneca
Ironwood Pharmaceuticals
Prestige Consumer Healthcare
Ardelyx

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment